Methoxsalen

Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS™ CELLEX™ Photopheresis System Treatment at the 2024 Tandem Meetings

Retrieved on: 
星期三, 二月 21, 2024
Thermal, Bangladesh Technical Education Board, Pulmonary embolism, Hypotension, Mallinckrodt, Anemia, Month, NIH, PUVA, Meta-analysis, Erythroderma, Excipient, Safety, PUVA therapy, Pain, Infection, Quality of life (healthcare), Deep vein thrombosis, Photopheresis, Artifact, FFS, ECP, Risk, OS, Graft-versus-host disease, Society, Extracorporeal, Methoxsalen, Patient, Systematic review, Burns, Transplant, Massachusetts General Hospital, Sunlight, Literature, Clutch (eggs), Environment, Pharmaceutical industry

DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced a poster presentation of findings from a systematic literature review and meta-analysis of the safety, efficacy, and real-world outcomes of extracorporeal photopheresis (ECP) treatment for patients with steroid-refractory chronic graft-versus-host disease (SR-cGvHD).1 An analysis of 47 studies reporting on the THERAKOS™ CELLEX™ Photopheresis System showed that treatment of SR-cGvHD with ECP was associated with improvements in patients' overall survival (OS), failure-free survival (FFS), and overall response rate (ORR).1 The results will be shared in a poster presentation at the 2024 Tandem Meetings, the combined Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) taking place February 21-24, 2024 in San Antonio, TX.

Key Points: 
  • Skin-specific response at Months 2-3 and at Months 4-6 were 34.86% (95% CI: 13.26-65.21) and 54.22% (95% CI: 35.67-71.67), respectively.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economics outcomes may not be solely attributable to THERAKOS ECP.
  • THERAKOS™ Photopheresis is contraindicated in:
    THERAKOS™ Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available.
  • Please refer to the THERAKOS™ CELLEX™ Photopheresis System Operator Manual for a complete list of warnings and precautions and adverse events.

JS Global's SharkClean® App Redesign Receives Shark's Record-High App Store Rating

Retrieved on: 
星期五, 五月 20, 2022
Software, Company, Ninja, Solution, Vacuum, B Corporation (certification), Barrocas, Industry, Partnership, SharkNinja, App Store (iOS/iPadOS), Travel, Sand, Map, Methoxsalen, 3D, Satellite navigation device

Going forward, the SharkClean app will serve as the center for the robot vacuum customer-brand relationship, launch new features and drive customer satisfaction.

Key Points: 
  • Going forward, the SharkClean app will serve as the center for the robot vacuum customer-brand relationship, launch new features and drive customer satisfaction.
  • SharkNinja is part of JS Global Lifestyle Company Limited (Hong Kong: 1691), a world-leading producer of small household appliances.
  • "The success of the overhauled SharkClean app is a testament to the hard work of the SharkNinja and ustwo teams.
  • Going forward, JS Global will be able to tailor the SharkClean app experience to the needs of different markets and support the Company's international and product expansion.

TYME Technologies, Inc. Announces Exploration of Strategic Options

Retrieved on: 
星期二, 三月 29, 2022
Evotec, Company, Private Securities Litigation Reform Act, Cancer, Clinical trial, Risk, Lung, Cell death, MOA, Forward-looking statement, Sarcoma, Board, Compliance, Prostate, Breast, AACR, SEC, Strategic planning, Biotechnology, Research, American Association, Oxidative stress, Board of directors, Methoxsalen, U.S. Securities and Exchange Commission, Learning, MPS, Association, American Association for Cancer Research, Phenytoin, Nasdaq, COVID-19, Sirolimus, GLOBE, Uncertainty, Annual report, Breast cancer, Patient, Disease, Phase, Pharmaceutical industry, TYME

BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value.

Key Points: 
  • BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value.
  • Notwithstanding the discontinuation of its most advanced clinical trial, the Company believes there are additional opportunities that could enhance value for TYME stockholders.
  • TYME believes that being well-capitalized affords it the ability to consider a wide range of strategic options and therefore has commenced a formal process with Moelis & Company LLC.
  • The goal of the strategic evaluation process is to ensure that we are exploring a range of possible options to maximize value for our stockholders.

TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
星期三, 三月 9, 2022
Nasdaq, AACR, Oxidative stress, Lung, American Association for Cancer Research, Twitter, Cell death, ORR, Methoxsalen, Risk, Compliance, Company, Breast, Prostate, Research, Department, Sirolimus, Sarcoma, Â, Clinical trial, Hematological Cancer Research Investment and Education Act, MedStar Health, Annual report, U.S. Securities and Exchange Commission, Cancer, Private Securities Litigation Reform Act, Georgetown University, GLOBE, Doctor of Philosophy, Breast cancer, Patient, Neoplasm, American Association, OASIS, Uncertainty, Population, COVID-19, MPS, Phenytoin, Disease, Toxicity, Association, Poster, SARS, Forward-looking statement, LinkedIn, ER, Pharmaceutical industry, Medical imaging, Facebook, TYME

BEDMINSTER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the availability of the poster abstract, “SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor positive breast cancer,” which was submitted by researchers from Georgetown University. The abstract will be presented by Dr. Ayesha Shajahan-Haq at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA. Dr. Shajahan-Haq, PhD is an Assistant Professor in the Department of Tumor Biology at Georgetown University, and her research focuses on resistance mechanisms in breast cancer.

Key Points: 
  • The abstract will be presented by Dr. Ayesha Shajahan-Haq at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.
  • Dr. Shajahan-Haq, PhD is an Assistant Professor in the Department of Tumor Biology at Georgetown University, and her research focuses on resistance mechanisms in breast cancer.
  • In earlier studies, SM-88 showed encouraging efficacy in breast cancer patients, including patients with HR+/HER2- disease.
  • We are excited to see more preclinical data to deepen our understanding of SM-88's utility in this setting.

Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China

Retrieved on: 
星期四, 三月 3, 2022
Purging disorder, Security (finance), Degenerative disease, Neutropenia, Urine, Enoxacin, U.S. Securities and Exchange Commission, Tongue, Hypertension, ALS, CYP1A2, News, FDA, Therapy, Drug development, Anaphylaxis, LinkedIn, Company, Development, Food, Caregiver, Jaundice, Water, Methoxsalen, Tablet, Vomiting, Fluvoxamine, Cough, Clobazam, Nausea, Fatigue, CNS, Fever, Mexiletine, Tiabendazole, Seizure, Riluzole, NASDAQ, Allergy, Lennox–Gastaut syndrome, Viscosity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, HIV disease progression rates, Liver, Central nervous system, Safety, Weakness, Abdominal pain, Vemurafenib, SZSE, Hepatotoxicity, Ciprofloxacin, GLOBE, Amyotrophic lateral sclerosis, Pharmaceutical industry

Around 85% of ALS patients suffer from a progressive loss of bulbar functionality.1 Swallowing food and liquids becomes more difficult over time.

Key Points: 
  • Around 85% of ALS patients suffer from a progressive loss of bulbar functionality.1 Swallowing food and liquids becomes more difficult over time.
  • This agreement with Haisco will allow ALS patients in China to access EXSERVAN, a riluzole oral film, which will provide a meaningful treatment option to those who have to discontinue their treatment because of difficulties swallowing a tablet.
  • Pursuant to the agreement, Haisco will lead the regulatory and commercialization activities for EXSERVAN in China.
  • EXSERVAN, an oral film formulation of riluzole, was developed by Aquestive using its PharmFilminnovative drug delivery technology.

TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

Retrieved on: 
星期三, 一月 26, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Oncology, COVID-19, Survival, Risk, Lung, Methoxsalen, MSC, Clinical trial, Uncertainty, U.S. Securities and Exchange Commission, Arm, Patient, Prostate, Annual report, Population, FOLFIRINOX, Phenytoin, Hematological Cancer Research Investment and Education Act, Twitter, Private Securities Litigation Reform Act, Research, Cancer, List of commonly used taxonomic affixes, Pancreatic cancer, Breast, Breast cancer, LinkedIn, MPS, Company, Cell death, Oxidative stress, Protein-bound paclitaxel, Compliance, MD, Learning, Sarcoma, Disease, Nasdaq, Pancreatic Cancer Action Network, Forward-looking statement, Gemcitabine, Pharmaceutical industry, Mobile phone, Medical imaging, Facebook, TYME, TYME Technologies, Inc., SM-88, TYME TECHNOLOGIES, INC., SM-88

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC) upon learning from the trial sponsor, Pancreatic Cancer Action Network (PanCAN), that it terminated the arm due to futility compared to the control of standard of care chemotherapy in second-line mPDAC.

Key Points: 
  • TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC) upon learning from the trial sponsor, Pancreatic Cancer Action Network (PanCAN), that it terminated the arm due to futility compared to the control of standard of care chemotherapy in second-line mPDAC.
  • The Precision Promise trial is an adaptive randomized Phase 2/3 trial in mPDAC for patients treated in both first-line and second-line therapies.
  • Given pancreatic cancers high mortality rate, we wanted to make a difference in the lives of these patients.
  • A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer.

TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor

Retrieved on: 
星期一, 九月 27, 2021
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Methoxsalen, RECIST, Clinical trial, Cancer, Cell death, Breast, Private Securities Litigation Reform Act, HER2, National Cancer Institute, Annual report, MedStar Health, Collection, NASDAQ, Survivor, Breast cancer, U.S. Securities and Exchange Commission, DNA, Patient, Population, LinkedIn, Biomarker, Sarcoma, JNCI, Phase, Georgetown University, Twitter, Lymphoma, Company, Phenytoin, Coronavirus, Woman, Prostate, Disease, Sirolimus, Risk, Preclinical development, COVID-19, Uncertainty, American Cancer Society, Research, Oxidative stress, Forward-looking statement, Incidence, Journal of the National Cancer Institute, Quality of life, Howlader, Lung, Pharmaceutical industry, Medical imaging, Breast Cancer, TYME Technologies, Inc., SM-88, BREAST CANCER, TYME TECHNOLOGIES, INC., SM-88

We are pleased to be collaborating with Georgetown University to work toward transforming the treatment landscape for these metastatic HR+/HER2- patients.

Key Points: 
  • We are pleased to be collaborating with Georgetown University to work toward transforming the treatment landscape for these metastatic HR+/HER2- patients.
  • Dosing the first patient is a critical milestone in advancing oral SM-88 as a potential treatment option prior to chemotherapy for this patient population.
  • This is a significant opportunity for TYME, and we look forward to providing updates as the OASIS trial progresses, concluded Cunningham.
  • The Company is enrolling a Phase II study evaluating SM-88 in breast cancer (HR+/HER2-) and continues enrollment of a Phase II study in high-risk metastatic sarcomas.